

Elbasvir + grazoprevir

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

| | |
|--------------------|---|
| INN | Elbasvir + grazoprevir |
| ATC codes | J05AP54 |
| Medicine type | Chemical agent |
| EML status history | Application rejected in 2017 (TRS 1006) for Chronic hepatitis C |
| Wikipedia | Elbasvir + grazoprevir  |
| DrugBank | Elbasvir  , Grazoprevir  |

Recommendations

Section Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 100 mg

Indications

Chronic hepatitis C

